Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vertex

- PMLiVE

Vertex wins FDA approval for cystic fibrosis therapy Orkambi

It is the combination therapy’s first regulatory approval

- PMLiVE

Top biotech firms saw sales jump in 2014

But rate of growth slowing from the past five years according to new analysis

Sanofi reception

Type 1 diabetes market to double to $13.6bn

New treatments will see this growth by 2023, according to GlobalData

- PMLiVE

The rising prevalence of diabetes in Europe

The condition is still an unstoppable epidemic

- PMLiVE

Lilly says peglispro tops Lantus in diabetes trials

New insulin demonstrates superiority to Sanofi’s product in cutting blood sugar levels

- PMLiVE

Lilly to use real-world data in diabetes collaboration

Partners with T1D Exchange to research ways to provide type 1 diabetes care

- PMLiVE

Disney and Lilly publish diabetes books online

Digital format for resource to help families with children who have type 1 diabetes

- PMLiVE

Medtronic and Lilly back JDRF’s diabetes walk

National sponsors of charity’s Walk to Cure Diabetes

- PMLiVE

Incivek decline forces Vertex job cuts

370 positions to be axed

- PMLiVE

Interview: Peter Meeus, Novo Nordisk

The managing director of Novo Nordisk UK discusses how education and new partnerships are helping fight the battle against the country’s worsening diabetes crisis

- PMLiVE

BMS and Vertex partner on oral hepatitis treatment

Will investigate combination of daclatasvir and VX-135

- PMLiVE

Vertex reports fatal reactions with hepatitis C drug

Adds boxed warning to Incivek

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links